Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Open-Label, Phase 2 Trial of Gemcitabine With or Without Bavituximab in Patients With Previously Untreated Stage IV Pancreatic Cancer

NCT01272791 is registered in ClinicalTrials.gov with Peregrine Pharmaceuticals as lead sponsor.

NCT NCT01272791
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01272791 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Open-Label, Phase 2 Trial of Gemcitabine With or Without Bavituximab in Patients With Previously Untreated Stage IV Pancreatic Cancer
Lead sponsor
Peregrine Pharmaceuticals
Phase
Phase 2
Overall status
Completed
Start date
January 31, 2011
Completion date
March 31, 2013
Enrollment
70 (actual)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic pancreatic cancer